6CM
683 Capital Management Portfolio holdings
AUM
$986M
This Quarter Return
-1.84%
1 Year Return
+26.79%
3 Year Return
+135.86%
5 Year Return
+188.43%
10 Year Return
+750.26%
AUM
$986M
AUM Growth
+$986M
(-3%)
Cap. Flow
+$1.37M
Cap. Flow
% of AUM
0.14%
Top 10 Holdings %
Top 10 Hldgs %
33.5%
Holding
242
New
22
Increased
37
Reduced
29
Closed
113
Top Buys
| 1 |
UnitedHealth
UNH
|
$27.2M |
| 2 |
AllianceBernstein
AB
|
$20.1M |
| 3 |
Centene
CNC
|
$16.1M |
| 4 |
Elevance Health
ELV
|
$11.7M |
| 5 |
GXO Logistics
GXO
|
$11.7M |
Top Sells
| 1 |
Globalstar
GSAT
|
$32.7M |
| 2 |
Occidental Petroleum Corporation Warrants to Purchase Common Stock
OXY.WS
|
$23.5M |
| 3 |
TG Therapeutics
TGTX
|
$15.9M |
| 4 |
Citigroup
C
|
$14.1M |
| 5 |
Carvana
CVNA
|
$11.1M |
Sector Composition
| 1 | Healthcare | 34.72% |
| 2 | Consumer Discretionary | 12.69% |
| 3 | Financials | 9.6% |
| 4 | Industrials | 8% |
| 5 | Technology | 5.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sarepta Therapeutics
SRPT
$2B
| $10.5M | 0.73% |
165,000
+63,000
| +62% | +$4.02M |
|
|
XHR
27
Xenia Hotels & Resorts
XHR
$1.36B
| $10.5M | 0.72% |
890,000
-111,990
| -11% | -$1.32M |
|
|
ITOS
28
DELISTED
iTeos Therapeutics
ITOS
| $10.4M | 0.72% |
1,750,000
+831,883
| +91% | +$4.97M |
|
|
MREO
29
Mereo BioPharma
MREO
$275M
| $10.4M | 0.72% |
4,635,000
+85,000
| +2% | +$191K |
|
30
ASML
ASML
$288B
| $10.4M | 0.72% |
15,650
| – | – |
|
31
Harmony Biosciences
HRMY
$2.13B
| $9.96M | 0.69% |
300,000
| – | – |
|
|
MRP
32
Millrose Properties, Inc.
MRP
$5.73B
| $9.41M | 0.65% |
+355,000
| New | +$9.41M |
|
33
Caesars Entertainment
CZR
$5.2B
| $9.38M | 0.65% |
375,000
+73,100
| +24% | +$1.83M |
|
34
Zevra Therapeutics
ZVRA
$514M
| $9.18M | 0.63% |
1,225,834
| – | – |
|
|
CRESY
35
Cresud
CRESY
$595M
| $9.17M | 0.63% |
830,000
-55,000
| -6% | -$608K |
|
36
Phathom Pharmaceuticals
PHAT
$848M
| $9.06M | 0.62% |
1,445,000
+420,000
| +41% | +$2.63M |
|
37
Howard Hughes
HHH
$4.48B
| $8.89M | 0.61% |
120,000
-15,000
| -11% | -$1.11M |
|
38
Amylyx Pharmaceuticals
AMLX
$876M
| $8.54M | 0.59% |
2,411,400
+481,400
| +25% | +$1.7M |
|
39
Western Alliance Bancorporation
WAL
$9.82B
| $8.45M | 0.58% |
110,000
+10,000
| +10% | +$768K |
|
40
Iovance Biotherapeutics
IOVA
$796M
| $7.99M | 0.55% |
2,400,000
+983,986
| +69% | +$3.28M |
|
|
SAGE
41
DELISTED
Sage Therapeutics
SAGE
| $7.95M | 0.55% |
1,000,000
+370,000
| +59% | +$2.94M |
|
42
Madrigal Pharmaceuticals
MDGL
$9.53B
| $7.81M | 0.54% |
23,576
+22,576
| +2,258% | +$7.48M |
|
|
ARMN
43
Aris Mining
ARMN
$1.85B
| $7.51M | 0.52% |
1,625,000
-173,900
| -10% | -$804K |
|
44
Viking Therapeutics
VKTX
$3.07B
| $7.37M | 0.51% |
305,000
+25,000
| +9% | +$604K |
|
45
Apellis Pharmaceuticals
APLS
$3.49B
| $7.28M | 0.5% |
333,000
-27,000
| -8% | -$590K |
|
46
Gossamer Bio
GOSS
$582M
| $6.71M | 0.46% |
6,100,000
-875,000
| -13% | -$963K |
|
|
SNDK
47
Sandisk Corporation Common Stock
SNDK
$7.62B
| $6.67M | 0.46% |
+140,000
| New | +$6.67M |
|
48
KBR
KBR
$6.39B
| $6.53M | 0.45% |
+131,000
| New | +$6.53M |
|
|
IRS
49
IRSA Inversiones y Representaciones
IRS
$1.07B
| $6.46M | 0.45% |
501,000
+101,000
| +25% | +$1.3M |
|
50
Eli Lilly
LLY
$658B
| $6.19M | 0.43% |
+7,500
| New | +$6.19M |
|